Psoriasis Biosimilars Market Outlook Signals Expansion To $13.79 Billion Through 2030

The market for psoriasis biosimilars has witnessed significant expansion in recent years, driven by several factors including the high costs of original biologic therapies and limited patient access. This growing sector is expected to continue its upward trajectory well into the next decade, supported by innovations, increased healthcare spending, and broader availability through various channels. Let's delve into the current market size, the forces propelling growth, key players, emerging trends, and segmentation within the psoriasis biosimilars landscape.

Strong Growth Outlook for the Psoriasis Biosimilars Market Size Through 2030
The psoriasis biosimilars market has experienced rapid growth historically, with the market size projected to increase from $8.16 billion in 2025 to $9.08 billion in 2026, representing a compound annual growth rate (CAGR) of 11.3%. This momentum is largely due to the expensive nature of reference biologics, restricted treatment access for patients, a rising number of moderate to severe psoriasis cases, growing physician familiarity, and the initial approval of TNF-alpha inhibitors.

Download a free sample of the psoriasis biosimilars market report:
https://thebusinessresearchcompany.com/sample_request?id=89643473&type=smp&name=Psoriasis%20Biosimilars%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Looking forward, the market is set to expand swiftly, reaching an estimated $13.79 billion by 2030 at a CAGR of 11.0%. Key factors driving this forecast include the introduction of new biosimilars for drugs like infliximab, etanercept, and adalimumab, the growth of hospital and online pharmacy networks, increased spending on dermatological healthcare, wider use of patient assistance programs, and a surge in clinical trials for innovative biosimilars. Notable ongoing trends encompass the rising adoption of cost-efficient biosimilars, enhanced focus on patient affordability and access, growth in both subcutaneous and intravenous delivery methods, broader distribution through hospital and retail pharmacies, and the development of targeted therapies tailored to various psoriasis types.

Prominent Companies Leading the Psoriasis Biosimilars Market
The psoriasis biosimilars sector features several influential players, including Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., and Alvotech hf.

View the full psoriasis biosimilars market report:
https://www.thebusinessresearchcompany.com/report/psoriasis-biosimilars-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

A noteworthy recent development occurred in September 2023, when Switzerland-based Sandoz Group AG partnered with South Korea's Samsung Bioepis to commercialize the biosimilar SB17 (ustekinumab). This collaboration aims to bring the biosimilar treatment-used for plaque psoriasis and other immune-mediated conditions-to markets in Europe and North America. Leveraging the strengths of both firms, the partnership seeks to widen patient access to affordable, high-quality immunology therapies while solidifying Sandoz's position as a leader in the global biosimilars market.

Key Factors Positively Influencing Psoriasis Biosimilars Market Growth
Leading market participants are focusing heavily on innovation by introducing biosimilars specifically designed for plaque psoriasis, aiming to improve treatment accessibility, lower healthcare expenditures, and enhance patient outcomes. Biosimilars serve as cost-effective, highly similar alternatives to approved biologic drugs that address the chronic autoimmune skin condition marked by red, scaly patches.

For example, in May 2025, Swiss pharmaceutical company Sandoz Group AG launched the Pyzchiva autoinjector, the first commercially available ustekinumab biosimilar autoinjector. This device is approved for adults with conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease, as well as for pediatric patients aged six years and older (weighing above 60 kg) with plaque psoriasis. Designed to improve treatment adherence and quality of life, the autoinjector includes features like precise automatic dosing, minimized injection pain, a compact size, and flexible storage, enabling easier self-administration.

Detailed Segmentation of the Psoriasis Biosimilars Market
This report breaks down the psoriasis biosimilars market into several important segments:
1) Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, and Other Biosimilars
2) Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
3) Route of Administration: Subcutaneous, Intravenous, Oral, Topical
4) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Further subcategories include:
- TNF-Alpha Inhibitors divided into Monoclonal Antibody Biosimilars and Fusion Protein Biosimilars
- Infliximab subtypes such as Remicade Biosimilars and CT-P13 Biosimilars
- Etanercept variants including Enbrel Biosimilars and SB4 Biosimilars
- Adalimumab forms such as Humira Biosimilars and ABP 501 Biosimilars
- Other Biosimilars including Ustekinumab and Secukinumab Biosimilars

This comprehensive segmentation provides a clear view of the various facets of the psoriasis biosimilars market, highlighting its complexity and the wide range of products, treatments, and distribution methods available.

Our 2026 market reports now include enhanced strategic insights through:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.